Minsheng Securities·2025-11-18 08:21Investment Rating - The report initiates coverage with a "Buy" rating for JD Health, indicating a positive outlook for the company's stock performance in the next 12 months [5]. Core Insights - JD Health's revenue for Q3 2025 reached 17.12 billion RMB, a year-on-year increase of 28.7%, with growth accelerating from 23.7% in Q2 [1][2]. - The company's operating profit surged by 125.3% year-on-year to 1.243 billion RMB, while the Non-IFRS net profit grew by 42.4% to 1.902 billion RMB, reflecting strong profit growth momentum [1][2]. - Strategic partnerships with major pharmaceutical companies like Eli Lilly and Bayer have reinforced JD Health's position as a leading platform for new specialty drugs [2][3]. Revenue and Profitability - Revenue growth is expected to continue, with projections of 71.01 billion RMB in 2025, 82.90 billion RMB in 2026, and 95.48 billion RMB in 2027, reflecting growth rates of 22.1%, 16.7%, and 15.2% respectively [4]. - Adjusted net profit is forecasted to be 6.256 billion RMB in 2025, with a growth rate of 30% [4]. Strategic Developments - JD Health is enhancing its digital healthcare services through collaborations with hospitals to develop AI-driven patient service platforms, aiming to improve patient experience and resource utilization [3]. - The company is expanding its online medical insurance payment services, which now cover nearly 200 million people, significantly increasing from the previous year [1][2]. Financial Metrics - The report provides a detailed financial forecast, including an expected EPS of 1.95 RMB for 2025, with a P/E ratio of 32 [4]. - The company's net profit margin is projected to improve from 10.1% in the first half of 2025 to 11.1% in Q3 2025, indicating enhanced operational efficiency [2].